Quick SummaryA new liquid biopsy method (not yet ready for routine care) analyzes immune-related signals in blood to predict which breast cancer patients may benefit from immunotherapy. In a study of stage 2-3 HER2-negative breast cancer patients (546 blood samples from 160 patients), blood transcriptomic patterns linked T-cell activity to better clinical outcomes. This differs from standard ctDNA liquid biopsies, which track tumor DNA. More validation in larger studies is needed before routine use.
|
A new blood test could help doctors predict which breast cancer patients are more likely to benefit from immunotherapy, according to a recent report on a breast cancer liquid biopsy study.
The research focuses on a liquid biopsy method that uses blood sampling rather than repeated tumor tissue biopsies. Although the test is not ready for routine care yet, it may point toward a more precise way of monitoring treatment and choosing cancer treatment strategies for certain patients.
Why This Blood Test Matters for Breast Cancer Care
Immunotherapy has changed cancer biology and treatment planning, especially for high-risk breast cancers such as triple negative breast cancer. However, not every patient will respond to treatment. Some patients experience side effects without sufficient benefit.
That is why doctors need better tools that can predict treatment response early. A blood test can predict useful patterns only if it shows a strong link between what appears in the blood and what happens inside the tumor.
In this study, researchers analysed blood samples from patients with stage 2 or 3 HER2-negative breast cancer. The team used repeated blood sampling to study immune activity during treatment. A related Vanderbilt report on breast cancer blood RNA sequencing noted that the study included 546 peripheral blood samples from 160 patients treated with chemotherapy alone or chemotherapy plus immunotherapy.
How Liquid Biopsy Predicts Response
Many people hear “liquid biopsy” and think only of circulating tumor DNA (ctDNA). Those tests look for DNA shed by cancer cells into the bloodstream. Levels of ctDNA can help show tumor burden, recurrence risk, and patterns linked to progression free survival, while also helping doctors decide whether targeted therapies may be useful in advanced breast cancer.
However, this new approach looks at immune-related signals in blood. In other words, it does not only ask whether cancer cells are leaving traces behind. Instead, it asks whether the immune system appears to be reacting in a way that predicts response to immunotherapy.
That difference matters. Immunotherapy depends on immune activation. Therefore, a blood-based immune signal may help predict treatment benefit more directly than a tumor DNA signal alone.
What the Clinical Trial Data Suggests
The study drew on patients in a clinical trial setting, which gives the findings greater weight than a small, informal review. Researchers found that blood transcriptomic patterns could help infer tumor subtype and predict treatment response during neoadjuvant chemoimmunotherapy.
The findings suggest that a test can predict which patients are more likely to respond by tracking immune changes over time. In particular, the research points to T-cell activity as an important clue. When immune cells show the right kind of activation, patients may have better clinical outcomes.
Still, this does not mean the test can predict every response today. It needs more testing in larger, independent groups before doctors can use it as a standard decision tool
How This Fits With Current Breast Cancer Treatment
The need for better prediction is clear because immunotherapy already plays an important role in some breast cancer care. The FDA has approved an immune checkpoint inhibitor for the treatment of high-risk early-stage TNBC in combination with chemotherapy before surgery, followed by additional treatment after surgery.
At the same time, liquid biopsy is already moving closer to everyday practice in other breast cancer settings. For example, the FDA recently approved vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer and also approved Guardant360 CDx as a companion diagnostic to identify eligible patients.
That approval does not make the new immunotherapy blood test ready for clinical use. However, it shows that blood-based testing is becoming more important in breast cancer treatment decisions.
What Still Needs to Happen Next
Several questions remain before this blood test could guide care. Researchers need to confirm the results in larger studies. They also need to define exact cutoffs, ideal blood sampling times, and how the test compares with tumor-based biomarkers.
Doctors also need proof that changing treatment based on the test improves patient outcomes. For example, could the test help identify patients who should switch therapy early? Could it spare some patients from unnecessary side effects? Could it help match others with clinical trial options sooner?
These are the questions that will decide whether this approach becomes a practical tool or remains a promising research finding.
| Potential Future Use | How This Blood Test Could Help | Current Limitation |
|---|---|---|
| Early Treatment Adjustment | May help doctors identify non-responders sooner and modify therapy before cancer progression occurs. | Researchers still need evidence that treatment changes based on the test improve survival outcomes. |
| Reduced Need for Tissue Biopsies | Could lower dependence on repeated invasive tumor sampling during treatment monitoring. | Blood-based immune monitoring has not yet replaced tumor-based biomarker analysis. |
| Personalized Immunotherapy Planning | May allow clinicians to better match immunotherapy intensity with a patient’s immune response profile. | No standardized immune-response scoring system currently exists for clinical use. |
| Clinical Trial Selection | Could help identify patients who may benefit most from experimental immunotherapy combinations. | Requires validation across larger and more diverse patient populations. |
What Patients Should Take Away
This study offers a hopeful step toward more personalized breast cancer immunotherapy. A liquid biopsy may one day help doctors predict treatment response, monitor immune activity, and adjust care earlier.
For now, patients should not view it as an available replacement for standard testing. Instead, it is a sign of where breast cancer research is heading: toward smarter, less invasive tools that connect blood-based signals with real clinical outcomes.
The key message is simple. A blood test could help predict breast cancer immunotherapy success, but more validation must come before it changes routine care.
